Mizukami, Takuro
Takahashi, Masaki
Sunakawa, Yu
Yuki, Satoshi
Kagawa, Yoshinori
Takashima, Atsuo
Kato, Kyoko
Hara, Hiroki
Denda, Tadamichi
Yamamoto, Yoshiyuki
Shiozawa, Manabu
Oki, Eiji
Okamoto, Wataru
Yoshino, Takayuki
Eguchi Nakajima, Takako
Funding for this research was provided by:
SCRUM Funds (Not aplicable)
Article History
Accepted: 4 April 2022
First Online: 7 May 2022
Declarations
:
: This work was supported by SCRUM-Japan Funds.
: Takuro Mizukami reports grants and personal fees from Taiho Pharmaceutical, Eli Lilly Japan, and Ono Pharmaceutical as well as personal fees from Otsuka Pharmaceutical Factory, Asahi Kasei Pharmaceutical, Merck Biopharma, Sanofi, and Takeda Pharmaceutical. Yu Sunakawa reports grants and personal fees from Taiho Pharmaceutical, Chugai Pharma, Takeda, Eli Lilly Japan, and Sanofi; personal fees from Bayer Yakuhin, Yakult Honsha, Bristol-Myers Squibb Japan, Merck Biopharma, Nippon Kayaku, Kyowa Hakko Kirin, Ono Pharmaceutical, MSD, and Daiichi Sankyo; and grants from Otsuka. Satoshi Yuki reports personal fees from Chugai Pharmaceutical Co., Ltd., Eli Lilly K.K., Takeda Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd, Bristol-Myers Squibb Co., Ltd., Taiho Pharmaceutical Co., Ltd., MSD K.K., Ono Pharmaceutical Co., Ltd., Medical & Biological Laboratories Co., Ltd., Yakult Honsha Co., Ltd., Merck Biopharma Co., Ltd., and Sanofi K.K. Yoshinori Kagawa reports personal fees from Bayer Co., Ltd., Chugai Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., Sanofi Co., Ltd., Eli Lilly Japan Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Merck Co., Ltd. Atsushi Takashima reports personal fees from Lilly, Taiho Pharmaceutical, Chugai Pharma, and Merck Serono; grants and personal fees from Ono Pharmaceutical and Takeda; and grants from Merck Sharp & Dohme, Eisai, Eisai, Bayer Yakuhin, and Bristol-Myers Squibb. Hiroshi Hara reports grants from AstraZeneca, Eisai, Elevar Therapeutics, Astellas, Beigene, Incyte, and Pfizer; grants and personal fees from Daiichi Sankyo, Dainippon Sumitomo Pharma, Merck Biopharma, MSD, Taiho, Chugai, Boehringer-Ingelheim, Ono Pharmaceutical, and BMS; and personal fees from Lilly, Yakult Honsha, Sanofi, Takeda, and Kyowa Hakko Kirin. Tadamichi Denda reports personal fees from Sawai Pharmaceutical Co and Sysmex as well as grants from MSD and Ono Pharmaceutical. Eiji Oki reports other from Chugai, Merck Biopharm, Eli Lilly, Takeda Pharm, Taiho Pharm, Bayer, and Takeda Pharm. Okamoto reports personal fees from Chugai Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb, Yakult Honsha, and Thermo Fisher Scientific as well as grants from Janssen Pharmaceutical. Takayuki Yoshino reports grants from Taiho Pharmaceutical, Sumitomo Dainippon Pharma, Ono Pharmaceutical, Chugai Pharmaceutical, Amgen, PAREXEL International, MSD, Daiichi Sankyo, and Sanofi. Takako Eguchi Nakajima reports grants from the National Cancer Research and Development Fund (26-A-4, 29-A-3), grants from Grant-in-Aid for Clinical Cancer Research (H26-144) from the Ministry of Health, Labour and Welfare of Japan, and grants from Japan Agency for Medical Research and Development (Grant numbers JP16ck0106139 and JP18ck0106351), during the conduct of the study; grants and personal fees from Sumitomo Dainippon Pharma Co., personal fees from Boehringer Ingelheim, Bristol-Myers Squibb, Novartis Japan, Bayer Yakuhin, Pfizer Japan Inc., Yakult Honsha Co., Nipro Co., Celltrion Healthcare Japan, Teijin Pharma, and Sawai Pharmaceutical Co., and grants and personal fees from Ono Pharmaceutical Co., Taiho Pharmaceutical Co., Amgen, Takeda Pharmaceutical Co., Chugai Pharmaceutical Co., Sanofi K.K., Nippon Kayaku Co., MSD K.K., Eli Lilly Japan K.K., Daiichi Sankyo Co., and Merck Serono Co., and grants from Eisai Co, outside the submitted work. Masaki Takahashi, Kyoko Kato, Youhei Yamamoto, and Manabu Shiozawa declare that they have no conflicts of interest that might be relevant to the contents of this article.
: This study is conducted following the Declaration of Helsinki and Ethical Guidelines for Medical and Health Research Involving Human Subjects and has been approved by the Institutional Review Boards and the Research Ethics Committee of St. Marianna University School of Medicine and National Cancer Center East.
: All participants provided written informed consent for participation.
: This article does not disclose any personally identifiable information of any of the participants. Hence, consent is not applicable.
: The data that support the findings of this study are available from the corresponding author upon reasonable request.
: TM: conceptualization, methodology, provision, data curation, writing of the original draft, visualization; MT: software, validation, formal analysis, data curation; YS: investigation, methodology, writing of the original draft; SY: investigation, writing, reviewing, and editing; YK: investigation, writing, reviewing, and editing; AT: investigation, writing, reviewing, and editing; KK: investigation, writing, reviewing, and editing; HH: investigation, writing, reviewing, and editing; TD: investigation, writing, reviewing, and editing; YY: investigation, writing, reviewing, and editing; MS: investigation, writing, reviewing, and editing; EO: investigation, writing, reviewing, and editing; WO: investigation, writing, reviewing, and editing; TY: investigation, writing, reviewing, and editing, supervision, funding acquisition; TEN: conceptualization, methodology, writing of the original draft, supervision, project administration, funding acquisition.